NextCure Updates Antibody Drug Programs, Expects $41.8M Cash by Year-End 2025
NextCure provided updates for its two antibody drug conjugate programs and reported a preliminary year-end 2025 cash position. SIM0505: Phase 1 dose escalation data expected in Q2 2026: SIM0505 is a novel ADC directed to cadherin-6, which is overexpressed in several cancers with limited expression in healthy tissues. SIM0505 features a proprietary topoisomerase 1 inhibitor payload, designed for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window. Data from the Phase 1 open-label dose escalation study are anticipated to be presented in the second quarter of 2026, including results from patients in the U.S. and China. The study is evaluating SIM0505 in patients with advanced solid tumors with a focus on gynecological cancers and an emphasis on platinum resistant ovarian cancer. The Company is adding clinical sites and increasing SIM0505 clinical drug supply in anticipation of initiating dose optimization in the first half of 2026. LNCB74: Ongoing Phase 1 dose escalation: LNCB74 is a novel ADC directed to B7-H4, overexpressed in several cancers with limited expression in healthy tissues. LNCB74 features a proprietary tumor-selective cleavable linker and a tubulin inhibitor monomethyl auristatin E payload. Dosing has commenced in higher dose cohorts for the ongoing open-label Phase 1 dose escalation study following the November 2025 protocol amendment announcement. Higher dose cohorts will prioritize patients with high B7-H4 expression in breast and gynecological cancers, while now including adenoid cystic carcinoma type 1. Proof-of-concept data, previously anticipated in the first half of 2026, is delayed to accommodate enrollment; NextCure now expects to provide a trial progress update in second half of 2026. As of December 31, 2025, NextCure is reporting preliminary cash, cash equivalents and marketable securities of approximately $41.8less than. These preliminary selected financial results are unaudited and subject to adjustment. The Company expects current financial resources to be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027.
Trade with 70% Backtested Accuracy
Analyst Views on NXTC
About NXTC
About the author
NextCure Completes $21.5 Million PIPE Financing Ahead of Phase 1 POC Data Releases in Early 2026
Funding Announcement: NextCure, Inc. has successfully closed a private placement of common stock, raising approximately $21.5 million, which will extend its cash runway into the first half of 2027.
Use of Proceeds: The funds will be utilized for general working capital and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74.
Private Placement Details: The offering involved the sale of 708,428 shares of common stock at $8.52 per share, along with pre-funded warrants for additional shares, all conducted under an exemption from the registration requirements of the Securities Act.
Company Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly targeting patients who do not respond to existing treatments.
NextCure Stock Rises 15% Following Private Placement News
Stock Performance: NextCure, Inc. (NXTC) shares rose 14.88% to $9.61 following the announcement of a private placement of approximately $21.5 million.
Funding Details: The company will issue 2,523,477 shares at $8.52 per share to institutional investors, with the funding expected to close around November 13, 2025.
Cash Runway Extension: The new funding will extend NextCure's cash runway into the first half of 2027 and support its antibody-drug-conjugate programs targeting CDH6 and B7-H4.
Trading Activity: The announcement led to unusually heavy trading volume for NXTC, with its stock price fluctuating between $2.65 and $9.61 over the past year.
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
Market Overview: U.S. stock futures showed mixed performance following a volatile trading session, with President Trump pressuring the Federal Reserve for interest rate cuts ahead of their upcoming decision on July 30. Analysts noted a bullish divergence in market breadth despite recent declines in certain sectors.
Company Highlights: Alphabet Inc. reported strong quarterly results while Tesla's performance fell short of expectations. Notable stock movements included Intel's significant drop after announcing layoffs, and several companies like NextCure and Linkhome Holdings saw substantial gains due to positive developments or IPOs.
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Deckers Outdoor Corporation Performance: Shares of Deckers Outdoor Corporation rose 11.6% in pre-market trading after reporting first-quarter earnings of 93 cents per share, exceeding analyst estimates, and quarterly revenue of $964.5 million, surpassing expectations.
Market Movements: Various stocks experienced significant changes in pre-market trading, with notable gainers including Linkhome Holdings (up 51%) and Coursera (up 22.5%), while losers included Incannex Healthcare (down 42.1%) and Intel Corporation (down 5.9%).
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
NextCure's Stock Surge: Shares of NextCure Inc. rose nearly 30% to $6.60 in premarket trading after positive preclinical results for its drug candidate NC605, aimed at treating brittle bone disease (osteogenesis imperfecta).
Drug Candidate Progress: NC605, an anti-Siglec-15 antibody, demonstrated improved bone microarchitecture and reduced fractures in a mouse model, with plans for an Investigational New Drug submission within 12 to 18 months, contingent on securing financial support.
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
Stock Surge: NextCure Inc.'s stock rose by 44.87% to $7.62 after presenting promising preclinical data for NC605, a potential treatment for brittle bone disease, which showed improved bone microarchitecture and reduced fracture incidence.
Strategic Developments: The company has also formed a strategic partnership with Simcere Zaiming to develop a new antibody-drug conjugate for solid tumors, indicating ongoing advancements in its research and development efforts despite recent stock volatility.
NextCure Completes $21.5 Million PIPE Financing Ahead of Phase 1 POC Data Releases in Early 2026
Funding Announcement: NextCure, Inc. has successfully closed a private placement of common stock, raising approximately $21.5 million, which will extend its cash runway into the first half of 2027.
Use of Proceeds: The funds will be utilized for general working capital and to support proof of concept data readouts for two antibody drug conjugate programs, SIM0505 and LNCB74.
Private Placement Details: The offering involved the sale of 708,428 shares of common stock at $8.52 per share, along with pre-funded warrants for additional shares, all conducted under an exemption from the registration requirements of the Securities Act.
Company Overview: NextCure is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly targeting patients who do not respond to existing treatments.
NextCure Stock Rises 15% Following Private Placement News
Stock Performance: NextCure, Inc. (NXTC) shares rose 14.88% to $9.61 following the announcement of a private placement of approximately $21.5 million.
Funding Details: The company will issue 2,523,477 shares at $8.52 per share to institutional investors, with the funding expected to close around November 13, 2025.
Cash Runway Extension: The new funding will extend NextCure's cash runway into the first half of 2027 and support its antibody-drug-conjugate programs targeting CDH6 and B7-H4.
Trading Activity: The announcement led to unusually heavy trading volume for NXTC, with its stock price fluctuating between $2.65 and $9.61 over the past year.
US Stocks Likely To Open On A Mixed Note: Intel, Philips 66, Centene, Charter Earnings In Focus
Market Overview: U.S. stock futures showed mixed performance following a volatile trading session, with President Trump pressuring the Federal Reserve for interest rate cuts ahead of their upcoming decision on July 30. Analysts noted a bullish divergence in market breadth despite recent declines in certain sectors.
Company Highlights: Alphabet Inc. reported strong quarterly results while Tesla's performance fell short of expectations. Notable stock movements included Intel's significant drop after announcing layoffs, and several companies like NextCure and Linkhome Holdings saw substantial gains due to positive developments or IPOs.
Why Deckers Outdoor Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Deckers Outdoor Corporation Performance: Shares of Deckers Outdoor Corporation rose 11.6% in pre-market trading after reporting first-quarter earnings of 93 cents per share, exceeding analyst estimates, and quarterly revenue of $964.5 million, surpassing expectations.
Market Movements: Various stocks experienced significant changes in pre-market trading, with notable gainers including Linkhome Holdings (up 51%) and Coursera (up 22.5%), while losers included Incannex Healthcare (down 42.1%) and Intel Corporation (down 5.9%).
NextCure Soars On Encouraging Preclinical Data Of Brittle Bone Disease Drug Candidate
NextCure's Stock Surge: Shares of NextCure Inc. rose nearly 30% to $6.60 in premarket trading after positive preclinical results for its drug candidate NC605, aimed at treating brittle bone disease (osteogenesis imperfecta).
Drug Candidate Progress: NC605, an anti-Siglec-15 antibody, demonstrated improved bone microarchitecture and reduced fractures in a mouse model, with plans for an Investigational New Drug submission within 12 to 18 months, contingent on securing financial support.
Nextcure Stock Skyrockets Nearly 45% In After-Hours Trading After Sharing Preclinical Data For Brittle Bone Disease
Stock Surge: NextCure Inc.'s stock rose by 44.87% to $7.62 after presenting promising preclinical data for NC605, a potential treatment for brittle bone disease, which showed improved bone microarchitecture and reduced fracture incidence.
Strategic Developments: The company has also formed a strategic partnership with Simcere Zaiming to develop a new antibody-drug conjugate for solid tumors, indicating ongoing advancements in its research and development efforts despite recent stock volatility.
